(123) developed a dual-function nanoplatform that can deliver programmed death-ligand 1 (PD-L1) antibodies and tumor necrosis factor-alpha (TNF-α) siRNA to the HNSCC tumor microenvironment. The gene discussed is CD274; the disease is neoplasm.